Kałużna Aleksandra, Jura-Półtorak Agnieszka, Derkacz Alicja, Jaruszowiec Julia, Olczyk Krystyna, Komosinska-Vassev Katarzyna
Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland.
City Hospitals of Chorzów, 41-500 Chorzów, Poland.
J Clin Med. 2023 Jun 28;12(13):4339. doi: 10.3390/jcm12134339.
The aim of this research was to investigate potential new biomarkers which could be used in the clinical practice of ulcerative colitis (UC). Given the crucial role of intestinal barrier integrity and inflammation in the pathogenesis of UC, the serum profile of proteins linked to intestinal barrier and pro-inflammatory neutrophil products may be useful in diagnosing and monitoring the activity of the disease. We measured serum levels of proguanylin (pro-GN), S100A12, and pentraxin 3 (PTX3) in 31 patients with UC before and after a year of biological treatment, as well as in 20 healthy individuals. Significant differences in the serum profiles of pro-GN (5.27 vs. 11.35, < 0.001), S100A12 (39.36 vs. 19.74, < 0.001) and PTX3 (3197.05 vs. 1608.37, < 0.001) were observed between pre-treatment patients with UC and healthy individuals. Furthermore, in UC patients prior to treatment, the levels of S100A12 ( < 0.0005; r = 0.628) and PTX3 ( < 0.05; r = 0.371) were correlated with disease activity as measured by the Mayo scale. Following a year of biological treatment with adalimumab, the concentration of pro-GN significantly increased (5.27 vs. 6.68, < 0.005) in the blood of UC patients, while the level of PTX-3 decreased (3197.05 vs. 1946.4, < 0.0001). Our study demonstrates the usefulness of pro-GN, S100A12, and PTX3 measurements in diagnosing and monitoring the activity of UC.
本研究的目的是探究可用于溃疡性结肠炎（UC）临床实践的潜在新型生物标志物。鉴于肠道屏障完整性和炎症在UC发病机制中的关键作用，与肠道屏障和促炎性中性粒细胞产物相关的血清蛋白谱可能有助于诊断和监测该疾病的活动。我们测量了31例接受生物治疗一年前后的UC患者以及20名健康个体血清中前鸟苷素（pro-GN）、S100A12和五聚素3（PTX3）的水平。在未经治疗的UC患者和健康个体之间，观察到pro-GN（5.27对11.35，<0.001）、S100A12（39.36对19.74，<0.001）和PTX3（3197.05对1608.37，<0.001）血清谱存在显著差异。此外，在治疗前的UC患者中，S100A12（<0.0005；r = 0.628）和PTX3（<0.05；r = 0.371）的水平与梅奥量表测量的疾病活动相关。在用阿达木单抗进行一年的生物治疗后，UC患者血液中pro-GN浓度显著升高（5.27对6.68, <0.005），而PTX-3水平下降（3197.05对1946.4，<0.0001）。我们的研究证明了测量pro-GN、S100A12和PTX3在诊断和监测UC活动中的实用性。
